Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 24
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
AIDS ; 38(7): 1003-1011, 2024 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-38411600

RESUMO

OBJECTIVES: Cognitive impairment persists in virally suppressed people with HIV (VS-PWH) especially in higher order domains. One cortical circuit, linked to these domains, is regulated by N -acetyl-aspartyl glutamate (NAAG), the endogenous agonist of the metabotropic glutamate receptor 3. The enzyme glutamate carboxypeptidase II (GCPII) catabolizes NAAG and is upregulated in aging and disease. Inhibition of GCPII increases brain NAAG and improves learning and memory in rodent and primate models. DESIGN: As higher order cognitive impairment is present in VS-PWH, and NAAG has not been investigated in earlier magnetic resonance spectroscopy studies (MRS), we investigated if brain NAAG levels measured by MRS were associated with cognitive function. METHODS: We conducted a retrospective analysis of 7-Tesla MRS data from a previously published study on cognition in older VS-PWH. The original study did not separately quantify NAAG, therefore, work for this report focused on relationships between regional NAAG levels in frontal white matter (FWM), left hippocampus, left basal ganglia and domain-specific cognitive performance in 40 VS-PWH after adjusting for confounds. Participants were older than 50 years, negative for affective and neurologic disorders, and had no prior 3-month psychoactive-substance use. RESULTS: Higher NAAG levels in FWM were associated with better attention/working memory. Higher left basal ganglia NAAG related to better verbal fluency. There was a positive relationship between hippocampal NAAG and executive function which lost significance after correction for confounds. CONCLUSION: These data suggest brain NAAG serves as a biomarker of cognition in VS-PWH. Pharmacological modulation of brain NAAG warrants investigation as a therapeutic approach for cognitive deficits in VS-PWH.


Assuntos
Encéfalo , Dipeptídeos , Infecções por HIV , Humanos , Masculino , Pessoa de Meia-Idade , Feminino , Infecções por HIV/complicações , Infecções por HIV/tratamento farmacológico , Infecções por HIV/psicologia , Estudos Retrospectivos , Encéfalo/metabolismo , Idoso , Espectroscopia de Ressonância Magnética , Cognição , Disfunção Cognitiva/metabolismo , Resposta Viral Sustentada
2.
Clin Pharmacol Ther ; 115(4): 758-773, 2024 04.
Artigo em Inglês | MEDLINE | ID: mdl-38037471

RESUMO

pyDarwin is an open-source Python package for nonlinear mixed-effect model selection. pyDarwin combines machine-learning algorithms and NONMEM to perform a global search for the optimal model in a user-defined model search space. Compared with traditional stepwise search, pyDarwin provides an efficient platform for conducting an objective, robust, less labor-intensive model selection process without compromising model interpretability. In this tutorial, we will begin by introducing the essential components and concepts within the package. Subsequently, we will provide an overview of the pyDarwin modeling workflow and the necessary files needed for model selection. To illustrate the entire process, we will conclude with an example utilizing quetiapine clinical data.


Assuntos
Algoritmos , Software , Humanos , Aprendizado de Máquina , Dinâmica não Linear , Fluxo de Trabalho
4.
Br J Clin Pharmacol ; 88(10): 4623-4632, 2022 10.
Artigo em Inglês | MEDLINE | ID: mdl-35949044

RESUMO

AIMS: Cabotegravir delivered as a long-acting intramuscular injection has shown superior efficacy to oral tenofovir-emtricitabine as pre-exposure prophylaxis (PrEP) for HIV. Cabotegravir pharmacokinetics (PK), like those of other long-acting depot preparations, exhibit variability between individuals and between injection occasions. The aim of this study is to describe the population pharmacokinetics of long-acting cabotegravir (CAB-LA). METHODS: Using available PK measurements from 133 participants in the HIV Prevention Trials Network (HPTN) 077 trial, we analysed CAB-LA PK data using nonlinear mixed-effects modelling to develop a population PK model. RESULTS: A two-compartment model with first order absorption best described the CAB-LA PK. The analysis identified between-occasion variability (BOV, i.e., differences in PK within one individual from one injection to the next) as a significant covariate affecting the absorption rate, with an estimated contribution of BOV to PK variability on the absorption rate (ka ) of 38.5%. Sex and body weight were identified as significant covariates influencing the absorption rate and apparent clearance of CAB-LA after intramuscular injection at various doses and frequencies. Male participants had 67% higher ka than female participants. Serially adding to the model body weight on clearance, sex on ka , and BOV on ka led to a decrease in the objective function value (OFV) of 24.4, 36 and 321.4, respectively. CONCLUSION: The public availability of this model will facilitate and enable a wide variety of future clinically relevant simulations to inform the optimal use of CAB-LA.


Assuntos
Fármacos Anti-HIV , Infecções por HIV , Peso Corporal , Dicetopiperazinas , Feminino , Infecções por HIV/tratamento farmacológico , Infecções por HIV/prevenção & controle , Humanos , Injeções Intramusculares , Masculino , Piridonas
5.
Neuropharmacology ; 194: 108447, 2021 08 15.
Artigo em Inglês | MEDLINE | ID: mdl-33450276

RESUMO

Patients with late-life depression (LLD) have a more variable response to pharmacotherapy relative to patients with mid-life depression. Degeneration of the serotonergic system and lower occupancy of the initial target for antidepressant medications, the serotonin transporter (5-HTT), may contribute to variability in treatment response. The focus of this study was to test the hypotheses that lower cortical and limbic serotonin transporter (5-HTT) availability in LLD patients relative to controls and less 5-HTT occupancy by antidepressant medications would be associated with less improvement in mood and cognition with treatment in LLD patients. Twenty LLD patients meeting DSM-IV criteria for a current major depressive episode and 20 non-depressed controls underwent clinical and neuropsychological assessments, magnetic resonance imaging to measure gray matter volumes and high-resolution positron emission tomography (PET) scanning to measure 5-HTT before and after 10-12 weeks of treatment with Citalopram or Sertraline (patients only). Prior to treatment, 5-HTT was lower in LLD patients relative to controls in mainly temporal cortical and limbic (amygdala and hippocampus) regions. Gray matter volumes were not significantly different between groups. 5-HTT occupancy was detected throughout cortical, striatal, thalamic and limbic regions. The magnitude of regional 5-HTT occupancy by antidepressants was 70% or greater across cortical and sub-cortical regions, consistent with the magnitude of 5-HTT occupancy observed in mid-life depressed patients. Greater regional 5-HTT occupancy correlated with greater improvement in depressive symptoms and visual-spatial memory performance. These data support the hypothesis that serotonin degeneration and variability in 5-HTT occupancy may contribute to heterogeneity in treatment response in LLD patients.


Assuntos
Antidepressivos/uso terapêutico , Transtorno Depressivo Maior/tratamento farmacológico , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico , Proteínas da Membrana Plasmática de Transporte de Serotonina/metabolismo , Afeto/efeitos dos fármacos , Idoso , Idoso de 80 Anos ou mais , Envelhecimento , Encéfalo/metabolismo , Citalopram/uso terapêutico , Feminino , Humanos , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Imagem Molecular , Sertralina/uso terapêutico
6.
Am J Psychiatry ; 177(12): 1129-1139, 2020 12 01.
Artigo em Inglês | MEDLINE | ID: mdl-33256444

RESUMO

OBJECTIVE: Altering the metabotropic glutamate receptor 3 (mGluR3) by pharmacology or genetics is associated with differences in learning and memory in animals and humans. GRM3 (the gene coding for mGluR3) is also genome-wide associated with risk for schizophrenia. The neurotransmitter N-acetyl-aspartyl-glutamate (NAAG) is the selective endogenous agonist of mGluR3, and increasing NAAG may improve cognition. Glutamate carboxypeptidase II (GCPII), coded by the gene folate hydrolase 1 (FOLH1), regulates the amount of NAAG in the synapse. The goal of this study was to determine the relationship between FOLH1, NAAG levels, measures of human cognition, and neural activity associated with cognition. METHODS: The effects of genetic variation in FOLH1 on mRNA expression in human brain and NAAG levels using 7-T magnetic resonance spectroscopy (MRS) were measured. NAAG levels and FOLH1 genetic variation were correlated with measures of cognition in subjects with psychosis and unaffected subjects. Additionally, FOLH1 genetic variation was correlated with neural activity during working memory, as measured by functional MRI (fMRI). RESULTS: A missense mutation in FOLH1 (rs202676 G allele) was associated with increased FOLH1 mRNA in the dorsolateral prefrontal cortex of brains from unaffected subjects and schizophrenia patients. This FOLH1 variant was associated with decreased NAAG levels in unaffected subjects and patients with psychosis. NAAG levels were positively correlated with visual memory performance. Carriers of the FOLH1 variant associated with lower NAAG levels had lower IQ scores. Carriers of this FOLH1 variant had less efficient cortical activity during working memory. CONCLUSIONS: These data show that higher NAAG levels are associated with better cognition, suggesting that increasing NAAG levels through FOLH1/GCPII inhibition may improve cognition. Additionally, NAAG levels measured by MRS and cortical efficiency during working memory measured by fMRI have the potential to be neuroimaging biomarkers for future clinical trials.


Assuntos
Antígenos de Superfície/genética , Cognição , Dipeptídeos/metabolismo , Glutamato Carboxipeptidase II/genética , Memória de Curto Prazo/fisiologia , Transtornos Psicóticos/psicologia , Adolescente , Adulto , Antígenos de Superfície/metabolismo , Encéfalo/metabolismo , Estudos de Casos e Controles , Feminino , Glutamato Carboxipeptidase II/metabolismo , Humanos , Testes de Inteligência , Imageamento por Ressonância Magnética , Espectroscopia de Ressonância Magnética , Mutação de Sentido Incorreto , Córtex Pré-Frontal/metabolismo , Transtornos Psicóticos/metabolismo , Adulto Jovem
7.
Transl Psychiatry ; 10(1): 372, 2020 11 02.
Artigo em Inglês | MEDLINE | ID: mdl-33139710

RESUMO

The L-type calcium channel gene, CACNA1C, is a validated risk gene for schizophrenia and the target of calcium channel blockers. Carriers of the risk-associated genotype (rs1006737 A allele) have increased frontal cortical activity during working memory and higher CACNA1C mRNA expression in the prefrontal cortex. The aim of this study was to determine how the brain-penetrant calcium channel blocker, nimodipine, changes brain activity during working memory and other cognitive and emotional processes. We conducted a double-blind randomized cross-over pharmacoMRI study of a single 60 mg dose of oral nimodipine solution and matching placebo in healthy men, prospectively genotyped for rs1006737. With performance unchanged, nimodipine significantly decreased frontal cortical activity by 39.1% and parietal cortical activity by 42.8% during the N-back task (2-back > 0-back contrast; PFWE < 0.05; n = 28). Higher peripheral nimodipine concentrations were correlated with a greater decrease in activation in the frontal cortex. Carriers of the risk-associated allele, A (n = 14), had a greater decrease in frontal cortical activation during working memory compared to non-risk allele carriers. No differences in brain activation were found between nimodipine and placebo for other tasks. Future studies should be conducted to test if the decreased cortical brain activity after nimodipine is associated with improved working memory performance in patients with schizophrenia, particularly those who carry the risk-associated genotype. Furthermore, changes in cortical activity during working memory may be a useful biomarker in future trials of L-type calcium channel blockers.


Assuntos
Bloqueadores dos Canais de Cálcio , Memória de Curto Prazo , Nimodipina , Esquizofrenia , Bloqueadores dos Canais de Cálcio/farmacologia , Voluntários Saudáveis , Humanos , Masculino , Memória de Curto Prazo/efeitos dos fármacos , Nimodipina/farmacologia , Córtex Pré-Frontal , Esquizofrenia/tratamento farmacológico , Esquizofrenia/genética
9.
Am J Psychiatry ; 173(1): 53-9, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26481172

RESUMO

OBJECTIVE: Antipsychotic drugs target dopamine and serotonin receptors as well as Kv11.1 potassium channels encoded by KCNH2. Variable patient responses and a wide range of side effects, however, limit their efficacy. Slow metabolizer status and gene variants in KCNH2 associated with increased expression of Kv11.1-3.1, an alternatively spliced isoform of Kv11.1, are correlated with improved responses to antipsychotic medications. Here, the authors test the hypothesis that these effects may be influenced by differential drug binding to Kv11.1 channel isoforms. METHOD: Drug block of Kv11.1 isoforms was tested in cellular electrophysiology assays. The effects of drug metabolism and KCNH2 genotypes on clinical responses were assessed in patients enrolled in the multicenter Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). RESULTS: Risperidone caused greater in vitro block of the alternatively spliced Kv11.1-3.1 isoform than full-length Kv11.1-1A channels, whereas its metabolite paliperidone and other atypical antipsychotics have similar potencies for the two isoforms. In the CATIE study (N=362), patients with genotypes associated with increased Kv11.1-3.1 expression (N=52) showed a better treatment response to risperidone compared with other drugs, but this association was dependent on metabolism status. Patients with KCNH2 risk genotypes and slow metabolizer status (approximately 7% of patients) showed marked improvement in symptoms when treated with risperidone compared with patients with fast metabolizer status or without the KCNH2 risk genotypes. CONCLUSIONS: These data support the hypothesis that Kv11.1 channels play a role in the therapeutic action of antipsychotic drugs, particularly risperidone, and further highlight the promise of optimizing response with genotype-guided therapy for schizophrenia patients.


Assuntos
Canais de Potássio Éter-A-Go-Go/genética , Risperidona , Esquizofrenia , Adulto , Processamento Alternativo , Antipsicóticos/metabolismo , Antipsicóticos/farmacocinética , Canal de Potássio ERG1 , Feminino , Genótipo , Humanos , Masculino , Isoformas de Proteínas , Risperidona/metabolismo , Risperidona/farmacocinética , Esquizofrenia/tratamento farmacológico , Esquizofrenia/genética , Esquizofrenia/metabolismo , Resultado do Tratamento
10.
JAMA Psychiatry ; 71(6): 647-56, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24718902

RESUMO

IMPORTANCE: One approach to understanding the genetic complexity of schizophrenia is to study associated behavioral and biological phenotypes that may be more directly linked to genetic variation. OBJECTIVE: To identify single-nucleotide polymorphisms associated with general cognitive ability (g) in people with schizophrenia and control individuals. DESIGN, SETTING, AND PARTICIPANTS: Genomewide association study, followed by analyses in unaffected siblings and independent schizophrenia samples, functional magnetic resonance imaging studies of brain physiology in vivo, and RNA sequencing in postmortem brain samples. The discovery cohort and unaffected siblings were participants in the National Institute of Mental Health Clinical Brain Disorders Branch schizophrenia genetics studies. Additional schizophrenia cohorts were from psychiatric treatment settings in the United States, Japan, and Germany. The discovery cohort comprised 339 with schizophrenia and 363 community control participants. Follow-up analyses studied 147 unaffected siblings of the schizophrenia cases and independent schizophrenia samples including a total of an additional 668 participants. Imaging analyses included 87 schizophrenia cases and 397 control individuals. Brain tissue samples were available for 64 cases and 61 control individuals. MAIN OUTCOMES AND MEASURES: We studied genomewide association with g, by group, in the discovery cohort. We used selected genotypes to test specific associations in unaffected siblings and independent schizophrenia samples. Imaging analyses focused on activation in the prefrontal cortex during working memory. Brain tissue studies yielded messenger RNA expression levels for RefSeq transcripts. RESULTS: The schizophrenia discovery cohort showed genomewide-significant association of g with polymorphisms in sodium channel gene SCN2A, accounting for 10.4% of g variance (rs10174400, P = 9.27 × 10(-10)). Control individuals showed a trend for g/genotype association with reversed allelic directionality. The genotype-by-group interaction was also genomewide significant (P = 1.75 × 10(-9)). Siblings showed a genotype association with g parallel to the schizophrenia group and the same interaction pattern. Parallel, but weaker, associations with cognition were found in independent schizophrenia samples. Imaging analyses showed a similar pattern of genotype associations by group and genotype-by-group interaction. Sequencing of RNA in brain revealed reduced expression in 2 of 3 SCN2A alternative transcripts in the patient group, with genotype-by-group interaction, that again paralleled the cognition effects. CONCLUSIONS AND RELEVANCE: The findings implicate SCN2A and sodium channel biology in cognitive impairment in schizophrenia cases and unaffected relatives and may facilitate development of cognition-enhancing treatments.


Assuntos
Encéfalo/fisiologia , Cognição/fisiologia , Predisposição Genética para Doença/genética , Canal de Sódio Disparado por Voltagem NAV1.2/genética , Córtex Pré-Frontal/fisiopatologia , Esquizofrenia/genética , Psicologia do Esquizofrênico , Adolescente , Adulto , Encéfalo/metabolismo , Estudos de Casos e Controles , Feminino , Neuroimagem Funcional , Expressão Gênica/genética , Expressão Gênica/fisiologia , Estudo de Associação Genômica Ampla , Genótipo , Humanos , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Polimorfismo de Nucleotídeo Único/genética , Polimorfismo de Nucleotídeo Único/fisiologia , RNA Mensageiro/metabolismo , Esquizofrenia/metabolismo , Esquizofrenia/fisiopatologia , Irmãos , Adulto Jovem
11.
Am J Psychiatry ; 169(7): 725-34, 2012 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-22706279

RESUMO

OBJECTIVE: Antidopaminergic drugs bind to hERG1 potassium channels encoded by the gene KCNH2, which accounts for the side effect of QT interval prolongation. KCNH2 has also been associated with schizophrenia risk, and risk alleles predict increased expression of a brain-selective isoform, KCNH2 3.1, that has unique physiological properties. The authors assessed whether genetic variation associated with KCNH2 3.1 expression influences the therapeutic effects of antipsychotic drugs. METHOD: The authors performed a pharmacogenetic analysis of antipsychotic treatment response in patients with schizophrenia using data from two independent studies: a National Institute of Mental Health (NIMH) double-blind, placebo-controlled inpatient crossover trial (N=54) and the multicenter outpatient Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) study (N=364). The KCNH2 genotype that was previously associated with increased expression of KCNH2 3.1 in the brain was treated as a predictor variable. Treatment-associated changes in symptoms were evaluated in both groups with the Positive and Negative Syndrome Scale. The authors also analyzed time to discontinuation in the olanzapine arm of the CATIE study. RESULTS: In the NIMH study, individuals who were homozygous for the KCNH2 3.1 increased expression-associated T allele of rs1036145 showed significant improvement in positive symptoms, general psychopathology, and thought disturbance, while patients with other genotypes showed little change. In the CATIE study, analogous significant genotypic effects were observed. Moreover, individuals who were homozygous for the T allele at rs1036145 were one-fifth as likely to discontinue olanzapine. CONCLUSIONS: These consistent findings in two markedly different treatment studies support the hypothesis that hERG1-mediated effects of antipsychotics may not be limited to their potential cardiovascular side effects but may also involve therapeutic actions related to the brainspecific 3.1 isoform of KCNH2.


Assuntos
Antipsicóticos/uso terapêutico , Canais de Potássio Éter-A-Go-Go/genética , Variação Genética/genética , Esquizofrenia/tratamento farmacológico , Esquizofrenia/genética , Adulto , Alelos , Ensaios Clínicos como Assunto/estatística & dados numéricos , Canal de Potássio ERG1 , Feminino , Genótipo , Humanos , Desequilíbrio de Ligação/genética , Masculino , Isoformas de Proteínas/genética
12.
Arch Gen Psychiatry ; 67(9): 939-45, 2010 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-20819988

RESUMO

CONTEXT: The CACNA1C gene (alpha-1C subunit of the L-type voltage-gated calcium channel) has been identified as a risk gene for bipolar disorder and schizophrenia, but the mechanism of association has not been explored. OBJECTIVE: To identify the neural system mechanism that explains the genetic association between the CACNA1C gene and psychiatric illness using neuroimaging and human brain expression. DESIGN: We used blood oxygenation level-dependent (BOLD) functional magnetic resonance imaging (fMRI) to measure brain activation in circuitries related to bipolar disorder and schizophrenia by comparing CACNA1C genotype groups among healthy subjects. We tested the effect of genotype on messenger RNA (mRNA) levels of CACNA1C in postmortem human brain. A case-control analysis was used to determine the association of CACNA1C genotype with schizophrenia. SETTING: National Institutes of Health Clinical Center. PATIENTS: Healthy men and women of white race/ethnicity participated in the fMRI study. Postmortem samples from normal human brains were used for the brain expression study. Patients with schizophrenia and healthy subjects were used in the case-control analysis. MAIN OUTCOME MEASURES: BOLD fMRI, mRNA levels in postmortem brain samples, and genetic association with schizophrenia. RESULTS: The risk-associated single-nucleotide polymorphism (SNP rs1006737) in CACNA1C predicted increased hippocampal activity during emotional processing (P = .001 uncorrected, P((false recovery rate [FDR])) = .05, z = 3.20) and increased prefrontal activity during executive cognition (P = 2.8e-05 uncorrected, P(FDR) = .01, z = 4.03). The risk-associated SNP also predicted increased expression of CACNA1C mRNA in human brain (P = .002). CACNA1C was associated with schizophrenia in our case-control sample (odds ratio, 1.77; P = .03). CONCLUSIONS: The risk-associated SNP in CACNA1C maps to circuitries implicated in genetic risk for bipolar disorder and schizophrenia. Its effects in human brain expression implicate a molecular and neural system mechanism for the clinical genetic association.


Assuntos
Transtorno Bipolar/genética , Encéfalo/fisiopatologia , Canais de Cálcio Tipo L/genética , Variação Genética/fisiologia , Esquizofrenia/genética , Adulto , Transtorno Bipolar/diagnóstico , Transtorno Bipolar/fisiopatologia , Estudos de Casos e Controles , Feminino , Estudos de Associação Genética , Predisposição Genética para Doença , Genótipo , Humanos , Imageamento por Ressonância Magnética/métodos , Masculino , Vias Neurais/metabolismo , Vias Neurais/fisiopatologia , Oxigênio/sangue , Polimorfismo de Nucleotídeo Único , RNA Mensageiro/metabolismo , Esquizofrenia/diagnóstico , Esquizofrenia/fisiopatologia
13.
Neuroimage ; 53(3): 804-9, 2010 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-20080192

RESUMO

Imaging genetics provides a unique tool with which to explore and evaluate the functional impact of brain-relevant genetic polymorphisms with the potential to understand their impact on behavior. Because statistical association with clinical diagnosis does not establish biological significance nor identify a mechanism of risk, imaging genetics is a uniquely valuable strategy for extending statistical evidence with biological data. Applications include identifying biologic mechanisms and pathways that mediate individual differences in complex behaviors and vulnerability to disease, and conversely identifying genes that contribute to functional variation in brain circuitry. Additionally, neuroimaging genetics can validate data that suggest an association with psychiatric illness as well as providing evidence of the mechanism of risk. This review also outlines several critical principles of imaging genetics including a rational approach to the selection of candidate genes, the selection of task paradigms that could be plausibly linked to the biology of the gene of interest, and careful control of non-genetic factors. The future of imaging genetics holds great promise for brain research and for biologic validation of genetic validation in CNS disorders, but a disciplined application of the basic principles outlined in this review is critical.


Assuntos
Diagnóstico por Imagem/métodos , Técnicas Genéticas , Transtornos Mentais/diagnóstico , Transtornos Mentais/genética , Técnicas Genéticas/tendências , Humanos
14.
Gend Med ; 6(4): 522-43, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-20114004

RESUMO

BACKGROUND: An increasing number of studies have reported differences in the pharmacokinetics and/or pharmacodynamics of antidepressants between women and men. OBJECTIVES: This article updates previously published literature describing sex differences in the pharmacokinetics and pharmacodynamics of antidepressants, and examines specific issues that face women with psychiatric illness. METHODS: An English-language literature search was performed with the PubMed database (March 2003-December 2008) using combinations of the search terms sex, gender, and antidepressants. In addition, each antidepressant was identified in the 63rd edition of the Physicians' Desk Reference. RESULTS: The current data suggest that the pharmacokinetics of antidepressants can be substantially different between women and men. Likewise, the response to antidepressants can be quite variable, including sex differences in adverse effects and time to response. CONCLUSIONS: Despite the many sex differences reported, there is still little published work systematically evaluating potential sex differences in antidepressant pharmacokinetics and pharmacodynamics. More research is needed to guide the treatment of depression and other mental illnesses.


Assuntos
Antidepressivos/farmacocinética , Depressão/tratamento farmacológico , Depressão/metabolismo , Sistema Enzimático do Citocromo P-450/genética , Sistema Enzimático do Citocromo P-450/metabolismo , Depressão/psicologia , Feminino , Humanos , Masculino , Fatores Sexuais
15.
Ther Drug Monit ; 30(6): 674-81, 2008 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19057371

RESUMO

Maximal aminoglycoside (AG) killing requires that the ratio of peak serum concentrations (Cmax) to the minimum inhibitory concentration (MIC) of the pathogen exceeds by > or =10. This has been shown to hasten resolution of infection in the general patient population. It was postulated that critically ill patients, likely to have larger intravascular volumes, are underdosed. The primary aim was to determine Cmax to MIC target attainment rate in medical intensive care unit (MICU) patients. A retrospective review of MICU patients who received at least 1 intravenous dose and serum concentration of either gentamicin or tobramycin was performed. A population pharmacokinetic model was developed, and MIC distributions for AG were used in determining the Cmax/MIC and in calculating the probability of attaining the pharmacodynamic (PD) target. One hundred two unique patients with 211 AG concentrations were analyzed to determine population pharmacokinetic parameters. Mean maximum clearance (CL) was 3.14L/h (95% confidence interval: 1.26-4.54 L/h), and mean volume of distribution (V) was 53 L (95% confidence interval: 38-66.8 L/h). Glomerular filtration rate and standardized body weight were identified as significant covariates for clearance in the final model. Standardized body weight also significantly affected V. There was only a 20% and 40% probability that patients receiving 7 mg/kg of gentamicin and tobramycin, respectively, will achieve PD target over the range of MIC distributions. Based on these data, the majority of critically ill patients would not be predicted to achieve the PD target under current dosing regimens. This may be a result of intensive care unit patients having a larger volume of distribution than reported in the literature. Future recommendations for treating gram-negative infections in the MICU population include using initial doses of 7 mg/kg of either gentamicin or tobramycin, measuring Cmax after the first dose, and determining MIC for the pathogen(s) with adjustment of subsequent doses to achieve the PD target.


Assuntos
Antibacterianos/administração & dosagem , Antibacterianos/farmacocinética , Gentamicinas/administração & dosagem , Gentamicinas/farmacocinética , Tobramicina/administração & dosagem , Tobramicina/farmacocinética , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Antibacterianos/sangue , Antibacterianos/uso terapêutico , Bactérias/efeitos dos fármacos , Infecções Bacterianas/tratamento farmacológico , Estado Terminal , Relação Dose-Resposta a Droga , Farmacorresistência Bacteriana , Feminino , Gentamicinas/sangue , Gentamicinas/uso terapêutico , Humanos , Unidades de Terapia Intensiva , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Tobramicina/sangue , Tobramicina/uso terapêutico
16.
Neuropsychopharmacology ; 33(13): 3221-5, 2008 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18463627

RESUMO

Variability in serotonin (5-HT) function is associated with individual differences in normal mood and temperament, as well as psychiatric illnesses, all of which are influenced by amygdala function. This study evaluated the acute effects of 5-HT reuptake blockade on amygdala function using pharmacological functional MRI. Eight healthy men completed a double-blind balanced crossover study with the selective 5-HT reuptake inhibitor, citalopram (20 mg infused over 30 min), and normal saline. Amygdala reactivity in response to novel facial expressions was assessed on three successive scans, once before drug/placebo infusion, once early in the infusion, and once at the end of infusion. Acute citalopram administration resulted in concentration-dependent increases in human amygdala reactivity to salient stimuli. The current pattern of 5-HT-mediated amygdala reactivity may represent an important pathway through which SSRIs achieve an antidepressant effect. Intriguingly, our data may also reveal a mechanism contributing to clinical observations of extreme agitation, restlessness, and suicidal ideation in some individuals during acute SSRI treatment. Developing a comprehensive model of how 5-HT modulates human amygdala reactivity supporting behavioral and physiological arousal will be instrumental for our understanding of basic neurobehavioral processes, their dysfunction in psychiatric illnesses, and their contribution to mechanism of treatment response.


Assuntos
Tonsila do Cerebelo/efeitos dos fármacos , Tonsila do Cerebelo/metabolismo , Química Encefálica/efeitos dos fármacos , Química Encefálica/fisiologia , Citalopram/farmacologia , Serotonina/metabolismo , Adulto , Acatisia Induzida por Medicamentos/metabolismo , Acatisia Induzida por Medicamentos/fisiopatologia , Ansiedade/induzido quimicamente , Ansiedade/metabolismo , Ansiedade/fisiopatologia , Estudos Cross-Over , Transtorno Depressivo/tratamento farmacológico , Transtorno Depressivo/metabolismo , Transtorno Depressivo/fisiopatologia , Relação Dose-Resposta a Droga , Método Duplo-Cego , Expressão Facial , Humanos , Masculino , Pessoa de Meia-Idade , Testes Neuropsicológicos , Estimulação Luminosa , Terminações Pré-Sinápticas/efeitos dos fármacos , Terminações Pré-Sinápticas/metabolismo , Inibidores Seletivos de Recaptação de Serotonina/farmacologia , Adulto Jovem
17.
Curr Psychiatry Rep ; 10(1): 30-6, 2008 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-18269892

RESUMO

Safe, effective drug therapy in older adults requires an understanding of drug disposition and response in this population. Evidence suggests that physiologic changes during aging, including hepatic or renal function changes, contribute to pharmacokinetic differences. A major issue surrounding the study of older adults relates to the ability to study a large number of people in a minimally invasive way. Population pharmacokinetics provides a potential means of addressing this issue and a tool to evaluate drug exposure's magnitude and consistency. This article highlights examples of pharmacokinetic studies in psychiatry, in particular those conducted in older adults. It also reviews new drugs approved for treatment in psychiatry or neurology, many of which were developed as novel formulations (eg, extended-release transdermal film) with improved pharmacokinetic profiles or developed with regard to the actions of a specific enantiomer or metabolite.


Assuntos
Transtornos Mentais/tratamento farmacológico , Psicotrópicos/farmacocinética , Administração Cutânea , Idoso , Biotransformação/fisiologia , Ensaios Clínicos como Assunto , Preparações de Ação Retardada , Humanos , Transtornos Mentais/sangue , Taxa de Depuração Metabólica/fisiologia , Psicotrópicos/administração & dosagem , Psicotrópicos/efeitos adversos
18.
J Clin Pharmacol ; 48(2): 157-65, 2008 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-18199892

RESUMO

Response to antipsychotics is highly variable, which may be due in part to differences in drug exposure. The goal of this study was to evaluate the magnitude and variability of concentration exposure of olanzapine. Patients with Alzheimer's disease (n = 117) and schizophrenia (n = 406) were treated with olanzapine as part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Combined, these patients (n = 523) provided 1527 plasma samples for determination of olanzapine concentrations. Nonlinear mixed-effects modeling was used to determine the population pharmacokinetics of olanzapine, and patient-specific covariates were evaluated as potential contributors to variability in drug exposure. The population mean olanzapine clearance and volume of distribution were 16.1 L/h and 2150 L, respectively. Elimination of olanzapine varied nearly 10-fold (range, 6.66-67.96 L/h). Smoking status, sex, and race accounted for 26%, 12%, and 7% of the variability, respectively (P < .0001). Smokers cleared olanzapine 55% faster than non/past smokers (P < .0001). Men cleared olanzapine 38% faster than women (P < .0001). Patients who identified themselves as black or African American cleared olanzapine 26% faster than other races (P < .0001). Differences in olanzapine exposure due to sex, race, and smoking may account for some of the variability in response to olanzapine.


Assuntos
Doença de Alzheimer/tratamento farmacológico , Benzodiazepinas/uso terapêutico , Esquizofrenia/tratamento farmacológico , Fumar , Administração Oral , Adolescente , Adulto , Negro ou Afro-Americano/estatística & dados numéricos , Algoritmos , Doença de Alzheimer/etnologia , Doença de Alzheimer/metabolismo , Antipsicóticos/sangue , Antipsicóticos/farmacocinética , Antipsicóticos/uso terapêutico , Povo Asiático/estatística & dados numéricos , Benzodiazepinas/sangue , Benzodiazepinas/farmacocinética , Cromatografia Líquida , Feminino , Humanos , Indígenas Norte-Americanos/estatística & dados numéricos , Masculino , Taxa de Depuração Metabólica , Análise Multivariada , Olanzapina , Esquizofrenia/etnologia , Esquizofrenia/metabolismo , Fatores Sexuais , Espectrometria de Massas em Tandem , Distribuição Tecidual , Resultado do Tratamento , População Branca/estatística & dados numéricos
19.
Neuroimaging Clin N Am ; 17(4): 459-67, viii, 2007 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17983963

RESUMO

Neuroimaging technologies provide a powerful approach to exploring the genetic basis of individual differences in complex behaviors and vulnerability to neuropsychiatric illness. Functional MRI studies have established important physiologic links between genetic polymorphisms and robust differences in information processing within distinct brain regions and circuits that have been linked to the manifestation of various disease. Neuroimaging technologies represent a critical tool in efforts to understand the neurobiology of normal and pathologic behavioral states. Research capitalizing on neuroimagingbased integration will contribute to the identification of predictive markers and biologic pathways for neuropsychiatric disease vulnerability and the generation of novel targets for therapeutic intervention.


Assuntos
Comportamento/fisiologia , Mapeamento Encefálico , Encéfalo/fisiologia , Expressão Gênica , Polimorfismo Genético , Humanos
20.
Am J Geriatr Psychiatry ; 14(12): 993-1003, 2006 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-17138806

RESUMO

Although geriatric patients are the major recipients of drugs, most research during drug development is conducted in healthy younger adults. Safe and effective drug therapy in the elderly requires an understanding of both drug disposition and response in older individuals. One of the major issues in studying the elderly relates to the ability to study a large number of people in a minimally invasive way. Population pharmacokinetics can be used to model drug concentrations from a large population of sparsely sampled individuals. Population pharmacokinetics characterizes both the interindividual (between-subject) and intraindividual (within-subject) variability, and can identify factors that contribute to pharmacokinetic and pharmacodynamic variability. Population pharmacokinetics can be used to aid in designing large clinical trials by simulating virtual data based on the study design. It can also be used to assess consistency of drug exposure and evaluate its effect on clinical outcome. This article reviews the methods used in pharmacokinetic modeling, as well as providing examples of population pharmacokinetic modeling, highlighting its application to geriatric psychiatry.


Assuntos
Psiquiatria Geriátrica , Farmacocinética , Adulto , Idoso , Interações Medicamentosas , Monitoramento de Medicamentos/métodos , Humanos , Transtornos Mentais/tratamento farmacológico , Modelos Biológicos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...